Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Natural Bioactive Products and Alzheimer’s Disease Pathology: Lessons from Caenorhabditis elegans Transgenic Models

13 May 2022

Abstract excerpt

Alzheimer’s disease (AD) is an age-dependent, progressive disorder affecting millions of people. Currently, the therapeutics for AD only treat the symptoms. Although they have been used to discover new products of interest for this disease, mammalian models used to investigate the molecular determinants of this disease are often prohibitively expensive, time-consuming and very complex. On the other hand, cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholinesterase and Neurodegenerative Diseases
Share to Genetics, Aging, and Longevity in Model Organisms
Share to Medicinal Plants and Neuroprotection

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35645249
DOI: 10.3390/diseases10020028

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Natural Bioactive Products and Alzheimer’s Disease Pathology: Lessons from Caenorhabditis elegans Transgenic ModelsPMID 35645249Read ↗

Modeling Alzheimer’s Disease in Caenorhabditis elegansSemantic proximity Read ↗

Use of Caenorhabditis elegans as a model to study Alzheimer’s disease and other neurodegenerative diseasesSemantic proximity Read ↗

Studying the mechanisms of neurodegeneration: C. elegans advantages and opportunitiesSemantic proximity Read ↗

Utility of an improved model of amyloid-beta (Aβ1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer’s diseaseSemantic proximity Read ↗

<em>Caenorhabditis elegans</em> as a Model for Studying Nrf2/SKN-1 Activation in Alzheimer’s Disease: Plant Bioactive Compounds and Therapeutic TranslationSemantic proximity Read ↗

Understanding the molecular basis of Alzheimer’s disease using a Caenorhabditis elegans model systemSemantic proximity Read ↗

Caenorhabditis elegans as a possible model to screen anti-Alzheimer's therapeuticsSemantic proximity Read ↗

Transgenic C. elegans as a model in Alzheimer's research.Semantic proximity Read ↗

Invertebrate models of Alzheimer's diseaseSemantic proximity Read ↗

Synergistic toxicity between tau and amyloid drives neuronal dysfunction and neurodegeneration in transgenic C. elegansSemantic proximity Read ↗

Alzheimer's disease drug discovery: in vivo screening using Caenorhabditis elegans as a model for β-amyloid peptide-induced toxicitySemantic proximity Read ↗

Beyond Transgenic Mice: Emerging Models and Translational Strategies in Alzheimer’s DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.